GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Capex-to-Operating-Cash-Flow

Guardion Health Sciences (Guardion Health Sciences) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Guardion Health Sciences's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-0.76 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Guardion Health Sciences Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Guardion Health Sciences's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences Capex-to-Operating-Cash-Flow Chart

Guardion Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Guardion Health Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Guardion Health Sciences's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Capex-to-Operating-Cash-Flow falls into.



Guardion Health Sciences Capex-to-Operating-Cash-Flow Calculation

Guardion Health Sciences's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.004) / -4.37
=N/A

Guardion Health Sciences's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.755
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardion Health Sciences  (NAS:GHSI) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Guardion Health Sciences Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences (Guardion Health Sciences) Business Description

Traded in Other Exchanges
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.
Executives
Katharine Joan Cox officer: Chief Accounting Officer 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall officer: CEO & President 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff 10 percent owner 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff other: See Footnote 1 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs director 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes director, officer: Chief Executive Officer 2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano director 131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin officer: Chief Accounting Officer 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan officer: Chief Commercial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans director, officer: Chief Scientific Officer 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans 10 percent owner 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth officer: General Counsel and Secretary 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten director 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Guardion Health Sciences (Guardion Health Sciences) Headlines